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ABSTRACT 
Objective: HPTLC Method for Simultaneous quantification of co-enzyme Q10 and α-tocopherol in bulk and capsule dosage form was developed and 
validated as per International Conference on Harmonization [(ICH) Q2 (R1)] guideline.  
Methods: The chromatograms were developed using a mobile phase of Toluene: ethyl acetate: chloroform (10:1:2 v/v/v) on Pre-coated silica 60F 
254 plates and quantified by densitometric absorbance mode at 280 nm.  
Results: The Rf values were 0.77 and 0.87 for co-enzyme Q10 and α-tocopherol, respectively. The linearity of the method was found to be in the 
concentration range of 0.6µg-1.8 µg/band for α-tocopherol and 2 µg-6 µg/band for co-enzyme Q10. The limits of detection and quantification were 
0.3154 and 0.9559 µg/band for α-tocopherol and 3.441 and 10.42 µg/band for co-enzyme Q10. 
Conclusion: Developed densitometric method was found to be robust, precise, accurate, and rapid and can be used to analyse fixed-dose capsule 
samples of co-enzyme Q10 and α-tocopherol. 
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HPTLC is a well-known, and versatile separation method which is 
type of planar chromatography involving the principle of adsorption. 
Now a days, HPTLC serves as a preferred analytical tool for 
quantitative analysis of drug substances in bulk, from their 
formulations, from the biological matrix, analysis of herbal extracts 
and standardization of herbal drugs [1]. 
Co-enzyme Q 10 (co-enzyme Q10; ubidecarenone) is a biologically 
active compound that is similar in chemical structure to 
menaquinones (vitamin K2). Being a part of a family of quinone 
compounds known as coenzyme Q, co-enzyme Q10 is characterized 
by a quinone ring attached to a repeating series of side-chain 
isoprene units (fig. 1). The number of isoprene units is denoted by 
the co-enzyme-X designation. In the case of co-enzyme Q10, there 
are 10 repeating isoprene units [2]. 
 
 
Fig. 1: Structure of co-enzyme Q10 
 
Co-enzyme Q10 was first discovered by researchers at the University 
of Wisconsin in 1957 [3]. It is highly water insoluble and lipophilic in 
nature [4]. It is also known for its effect, when combined with 
chemotherapy for treatment of cancer [5], prevention of low-density 
lipoprotein oxidation [6], antihypertensive functions [7], migraine 
headache treatment, neurodegenerative disease treatment and 
cardiovascular disease [8]. 
α-Tocopherol (vit. E), 2, 5, 7, 8-tetramethyl-2-[(2R, 8R) 4, 8, 12-
trimethyl tridecyl] 3, 4-dihydro-2H-chromene-6ol, encompasses 
eight molecules composed by a chromanol ring and a phytol side 
chain displaying identical functions: four tocopherols (α, β, γ and δ) 
and four tocotrienols (α, β, γ, and δ). Tocopherols have saturated 
side chain. The prefixes α, β, γ, and δ indicate the position of methyl 
groups on chromanol ring [9]. Theα-tocopherol is most abundant in 
nature (fig. 2) [10]. One α-tocopherol molecule can trap two peroxyl 
radicals responsible of lipid oxidation initiation [11]. Hence, this 
molecule protects membrane lipids against oxidation [12]. 
 
Fig. 2: Chemical structure of tocopherol 
 
Co-enzyme Q10 and α-tocopherol are nutrients that may play a 
protective role in the human body due to their antioxidant functions. 
They are commonly found together in supplement form and have 
been used to prevent and treat several conditions including heart 
disease, cancer and neurodegenerative diseases. 
Literature reveals that colorimetric method, HPLC methods, FT-NIR 
method are reported for estimation of the drug entities under study 
in single component or multicomponent formulations [13-21]. 
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HPTLC method for simultaneous estimation of α-Tocopherol and co-
enzyme Q10 is not reported. The objective of research work was to 
develop accurate, precise, specific and economic HPTLC method for 
the estimation of co-enzyme Q10 and α-tocopherol in bulk and 
marketed formulation and perform validation [22]. 
MATERIALS AND METHODS 
Materials and formulation 
Co-enzyme Q10 and α-tocopherol were purchased from Bulk 
Powders and Fluka Analytical, Sigma Aldrich respectively. 
Commercial Capsules containing co-enzyme Q10 (100 mg) and α-
tocopherol (30 mg) were used for the study. Merck HPTLC 
Aluminium plates precoated with silica gel 60 F254 
Reagents 
were procured 
from local scientific and chemical supplier.  
Chemicals of (A. R. and HPLC grade) were purchased from SD Fine 
Chemicals, Mumbai, Maharashtra, India.  
Instrumentation 
Details of HPTLC instrument are given in table 1. 
 
Table 1: HPTLC instrument specifications 
Parameter Specification 
HPTLC instrument  Camag HPTLC 
Applicator  Linomat 5 
Detection by  Scanner 3 
Visualizer Camag TLC visualizer 
HPTLC Syringe  100 and 500 µl 
TLC Plates Pre-coated silica 60F254 
Software  Win CATS 
 
Analytical method development 
Preparation of the standard stock solutions 
About 30 mg of α-tocopherol STD was weighed into 25 ml volumetric 
flask and the volume was made up to the mark with diluents [HPLC 
Grade Ethyl acetate: Methanol (50:50)] to make 1200 ppm stock solution 
(Solution A). Separately 100 mg of co-enzyme Q10 was weighed into 25 
ml volumetric flask and the volume was made up to the mark with 
diluent to make 4000 ppm stock solution (Solution B). 
Selection of detection wavelength 
Drug bands were scanned in the range of 200-700 nm and UV 
spectra were overlain. Both the drugs showed significant 
absorbance at 280 nm, which was selected as detection wavelength. 
Preparation of sample solutions 
Bulk-1 ml from stock solution A and 1 ml from stock solution B were 
mixed and diluted to 10 ml to make bulk mixture solution containing 
α-tocopherol 120 ppm and co-enzyme Q10 400 ppm stock solution. 
Capsule-As each capsule formulation contains 30 mg of α-tocopherol 
and 100 mg of co-enzyme Q10 the average weight of content of capsule 
formulation was found to be around 301.1 mg. Hence 300mg of 
formulation was taken and dissolved in 25 ml of diluent and further 1 ml 
of solution was diluted to 10 ml diluent to make mix solution of α-
tocopherol 120 ppm and co-enzyme Q10 400 ppm sample solution. 
Selection of stationary phase 
HPTLC Aluminium plates pre-coated with silica gel 60 F254 were 
selected as the stationary phase. 
Layer pre-washing 
Precoated TLC plates were prewashed with methanol to remove 
adsorbed material, impurities which include water vapours and 
other volatile substances from the atmosphere when they get 
exposed in the lab environment. 
Layer preconditioning 
Prewashed plates were placed in oven at 105 °C for 5 min prior to 
the sample application. 
Optimisation of chromatographic conditions 
Many preliminary trials were carried out for selection and optimisation 
of mobile phase composition and chamber saturation time. 
Analytical method validation 
Specificity 
The specificity of the method for assay was demonstrated by 
applying 10 µl band of STD, blank and sample solutions on the 
HPTLC plates for rectification of specificity of method. 
Linearity 
The linearity of peak area response for α-tocopherol and co-enzyme Q10 
was determined from 50 % to 150 % level of working concentration for 
both the STD. The mixed stock solutions of α-tocopherol and co-enzyme 
Q10 were diluted in five different known concentrations. Graphs of 
concentration (as x-value) versus area (as y-value) were plotted.  
Precision 
System precision 
System precision was evaluated from five replicate bands of 
standard as per proposed method. The Peak area, average and % 
RSD were calculated. 
Method precision 
The six sample solutions were prepared separately. Each sample 
solution was analysed as per proposed procedure. The % assay, 
average and % RSD were calculated. 
Intermediate precision  
The Intermediate precision was determined by comparison of two 
independent analysis on 2 different days. 
Robustness 
The influence of slightly changed parameters of the 
chromatographic conditions was tested according to ICH guidelines 
to demonstrate sufficient robustness of the method. The tests were 
carried out by applying standard solution by varying some of the 
parameters of chromatography mentioned in table 2. 
 
Table 2: Robustness parameters 
S. No. Parameters Working parameter -Change +Change 
1 Saturation Time (minute) 15 14 16 
2 Polar Solvent Volume (MeOH) 0.5 0.4 0.6 
3 Mobile Phase Volume 10 9 11 
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The accuracy was determined from recovery studies. A known but 
varying amount of STD was spiked into pre-analyzed formulation 
sample solution at 80%, 100% and 120% recovery levels of working 
concentration in triplicate. The spiked sample solution was analyzed 
according to the proposed procedure. The percentage recoveries 
were calculated against respective levels 
Limit of detection and limit of quantitation 
The values of Limit of Detection (LOD) and Limit of Quantitation 
(LOQ) were determined based on the standard deviation of the 
response and the slope of calibration graph. The quantitation was 
done with the help of formulae 1 and 2.  
LOD =  3.3 σ
S
 …. (1) 
𝐿𝐿𝐿𝐿𝐿𝐿 =  10 𝜎𝜎
𝑆𝑆
 …. (2) 
Where σ = Standard Deviation of replication, S = Slope of calibration 
curve 
RESULTS AND DISCUSSION 
Analytical method development 
The experimental conditions selected are shown in table 3. 
Selection of detection wavelength 
Both the drugs showed significant absorbance at 280 nm which was 
selected as detection wavelength. 
Analytical method validation 
Specificity 
The chromatograms of blank, standard mixture of co-enzyme Q10 and 
α-tocopherol and Sample mixture of co-enzyme Q10 and α-tocopherol 
in the formulation are shown in fig. 3, fig. 4 and fig. 5. By comparing the 
Chromatograms of the Blank solution, Standard solution and sample 
solution of co-enzyme Q10 and α-tocopherol, it was observed that no 
peak was co-eluted with the analyte band from blank solution. Purity 
of co-enzyme Q10 and α-tocopherolin STD and sample solution was 
observed to be satisfactory. Hence the method is considered to be 
specific as per the above-mentioned observations. 
 
Table 3: Optimized experimental conditions 
Parameter Specification 
Plate activation At 105 °C for 5 min 
Saturation time 15 min 
Wavelength of detection  280 nm 
Mobile phase chamber Twin trough Chamber (10x10 and 20x10) 
Photo-documentation White R Light 
Application volume 10 µl 
Retention factor of α-tocopherol 0.86 
Retention factor of co-enzyme Q10  0.77 
Room temperature 22 °C at the time of experimentation 
Type of application Band Type  
Storage conditions of sample and STD At 2-8 °C and in dark chamber 
Diluent HPLC grade ethyl acetate: methanol (50:50) 
 
 
Fig. 3: HPTLC chromatogram of Blank solution 
 
 
Fig.4 HPTLC chromatogram of Standard solution 
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Fig. 5: HPTLC chromatogram of sample solution (Formulation) 
 
Linearity 
The observations for linearity are listed in table 4 and a depiction in 
the form of 3D graph is shown in the fig. 6. The calibration curve for 
linearity is drawn and the correlation coefficient calculated as 
shown in fig. 7 and fig. 8. Method is considered to be linear as the 
correlation coefficient was found to be within acceptance criteria for 
both α-tocopherol and co-enzyme Q10. 
 
Table 4: Linearity study 
Conc. of α-tocopherol 
(ppm) 
Average peak area of α-
tocopherol 
Conc. of Co-enzyme Q10 
(ppm) 
Average peak area of Co-enzyme 
Q10 
60 2152 200 790 
90 3165 300 1545 
120 4125 400 2215 
150 5214 500 2896 
180 6214 600 3545 
 
 
Fig. 6: Linearity study 
 
 
Fig. 7: Linearity of α-tocopherol 
Kulkarni et al. 




Fig. 8: Linearity of co-enzyme Q10 
 
System precision 
The calculated peak area, average and % RSD are shown in table 5. 
The % RSD observed within acceptable limit indicates the precision 
of the system. 
Method precision 
The calculated % assay, average and % RSD for precision study are 
shown in table 6. Repeatability of Rf is depicted in fig. 9 and 10. The 
% RSD was observed within the limit, which indicates that the 
method has an acceptable level of precision. 
Intermediate precision 
The intermediate precision observations are shown in table 7 and 8. 
% RSD of % assay results from 6 determinations are within 
acceptance criteria for day 1 analysis and day 2 analysis. Hence the 
method of assay for α-tocopherol and co-enzyme Q10 from 
formulation is rugged. 
 
Table 5: System precision for α-tocopherol and co-enzyme Q10 
Band number Peak area of α-tocopherol Peak area of co-enzyme Q10 
1 4105 2201 
2 4106 2203 
3 4198 2215 
4 4107 2208 
5 4105 2215 
Mean 4124.2 2208.4 
SD 41.26 6.542171 




Table 6: Method precision for α-tocopherol and Co-enzyme Q10 
Sample no. % assay of α-tocopherol % assay of co-enzyme Q10 
1 100.13 98.75 
2 100.05 98.64 
3 99.78 98.22 
4 100.4 97.98 
5 99.61 100.04 
6 100.42 98.87 
Mean 100.07 98.75 
SD 0.32417 0.71558 





Fig. 9: Method precision 
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Fig. 10: Method precision-repeatability of Rf values 
 
Table 7: Intermediate precision for α-tocopherol 
Name of analyte S. No. Assay %w/w day 1 Assay %w/w day 2 
α-tocopherol 1 100.13 100.1 
2 100.05 98.6 
3 99.78 100.03 
4 100.4 99.82 
5 99.61 99.74 
6 100.42 99.89 
Average 100.07 99.69 
% RSD 0.32 0.56 




Table 8: Intermediate precision forco-enzyme Q10 
Name of analyte S. No. Assay %w/w day 1 Assay %w/w day 2 
 1 98.75 100.84 
2 98.64 100.71 
3 98.22 98.49 
4 97.98 101.71 
5 100.04 101.27 
6 98.87 99.43 
Average 99.58 100.41 
% RSD 0.72 1.21 




The observations for robustness are listed in table 9 and 10. The % 
RSD and system suitability parameters for results obtained with 
varied chromatographic conditions are within the limits. Hence, the 
method is robust. 
n=6 
Accuracy 
The calculated percentage recoveries against respective levels are 
mentioned in table 12 and 13. The % average recovery of α-tocopherol 
and co-enzyme Q10 formulation observed within acceptance criterion of 
98-102% indicates the accuracy of the method. 
 
Table 9: Robustness of method for α-tocopherol 
Robustness parameter Level % RSD RT Peak purity 
Saturation Time (minute) 14 0.45 0.86 OK 
15 0.75 0.86 OK 
16 0.88 0.87 OK 
Polar Solvent Volume (MeOH) 0.4 0.73 0.86 OK 
0.5 0.92 0.87 OK 
0.6 0.53 0.87 OK 
Mobile Phase Volume 9 0.94 0.86 OK 
10 0.61 0.87 OK 
11 0.64 0.87 OK 
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Table 10: Robustness of method for co-enzyme Q10 
Robustness parameter Level % RSD RT Peak purity 
Saturation Time (minute) 14 0.84 0.77 OK 
15 1.39 0.77 OK 
16 1.61 0.77 OK 
Polar Solvent Volume (MeOH) 0.4 1.70 0.77 OK 
0.5 1.34 0.77 OK 
0.6 0.97 0.78 OK 
Mobile Phase Volume 9 1.74 0.78 OK 
10 1.13 0.77 OK 
11 1.17 0.77 OK 
 
Table 12: Accuracy of a method for α-tocopherol 
Band Sample Sample recovery levels (%) Std wt. (spiked) Amount recovered % recovery Average % recovery 
1 Sample 1 80 24.10 24.05 99.79 99.77 
2 Sample 2 80 24.15 24.06 99.63 
3 Sample 3 80 24.13 24.10 99.88 
4 Sample 4 100 30.12 30.12 100.00 99.99 
5 Sample 5 100 30.18 30.15 99.90 
6 Sample 6 100 30.17 30.19 100.07 
7 Sample 7 120 36.06 36.06 100.00 100.02 
8 Sample 8 120 36.07 36.09 100.06 
9 Sample 9 120 36.12 36.12 100.00 
 
Table 13: Accuracy of method for co-enzyme Q10 
Band Sample Sample recovery levels (%) Std wt. 
(spiked) 
Amount recovered % recovery Average % recovery 
1 Sample 1 80 80.15  80.09 99.93 99.95 
2 Sample 2 80 80.12  80.15 100.04 
3 Sample 3 80 80.16  80.07 99.89 
4 Sample 4 100 100.10  100.12 100.02 99.93 
5 Sample 5 100 100.21  100.17 99.96 
6 Sample 6 100 100.23  100.03 99.80 
7 Sample 7 120 120.12  120.01 99.91 99.98 
8 Sample 8 120 120.15  120.15 100.00 
9 Sample 9 120 120.09  120.14 100.04 
 
Table 14: LOD and LOQ 
Drug Parameter Values obtained (µg/band) 
α-tocopherol LOD 0.3154  
LOQ 0.9559  
Co-enzyme Q10  LOD 3.441 
LOQ 10.42 
 
Limit of detection and limit of quantitation 
Values of LOD and LOQ calculated using slope of calibration plot 
(6.861 for co-enzyme Q10 and 33.91 for α-tocopherol) and standard 
deviation (0.71558 for co-enzyme Q10 and 0.32417 for α-
tocopherol) (table 14) 
DISCUSSION 
A novel HPTLC method is reported for simultaneous estimation of 
coenzyme Q 10 and α-tocopherol. The developed method is 
validated as per ICH Q2R1 guidelines. It was found to be simple and 
reproducible as compared to the reported methods [18-21]. The 
literature survey reveals HPLC, FT-NIR methods for simultaneous 
estimation of co-enzyme Q10 and α-tocopherol. The present study 
uses HPTLC method for the estimation of said drugs, which is more 
economical and less time consuming. 
CONCLUSION 
There is no HPTLC method reported for the simultaneous estimation 
of co-enzyme Q10 and α-tocopherol. The developed HPTLC method 
was found to be fast, simple, sensitive and economic. The method 
was validated and found to be specific, linear, accurate, precise and 
robust. Hence the developed novel HPTLC method can be 
conveniently adopted for routine analysis of the Co-enzyme Q10 and 
α-tocopherol in bulk and in capsule formulation. 
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